Richard De Abreu Lourenco

Applications to list drugs on the PBS are usually submitted by the manufacturers of those drugs. from shutterstock.com

November 27, 2017

We don’t need to change how we subsidise ‘breakthrough’ cancer treatments

Richard De Abreu Lourenco, University of Technology Sydney; Marion Haas, University of Technology Sydney, and Rosalie Viney, University of Technology Sydney

Some argue the current system of subsidising drugs in Australia needs changing to accommodate new cancer therapies. But two recent drug listings show the current system is working perfectly well.

The cost governments are willing to pay drug companies for medicines depends on the outcome the drug will provide. from www.shutterstock.com

November 20, 2017

Explainer: how is the price of medicine decided in Australia?

Rosalie Viney, University of Technology Sydney; Philip Haywood, University of Technology Sydney, and Richard De Abreu Lourenco, University of Technology Sydney

Have you ever wondered why some drugs are so cheap, and others so expensive? Here’s why.

The government’s attempt to introduce a $7 compulsory co-payment for visits to the doctor and pathology services has drawn widespread criticism. AAP Image/NEWZULU/PETER BOYLE

July 9, 2014

GP co‑payments: why price signals for health don’t work

Jane Hall, University of Technology Sydney and Richard De Abreu Lourenco, University of Technology Sydney

Arguments against health co-payments proposed in May’s federal budget will come to the fore again shortly as the Senate considers whether it will pass the necessary legislation. The government’s attempt…

3

0

We don’t need to change how we subsidise ‘breakthrough’ cancer treatments

Explainer: how is the price of medicine decided in Australia?

GP co‑payments: why price signals for health don’t work

Contact Richard for